Literature DB >> 20428944

Rifaximin for inflammatory bowel disease.

Mario Guslandi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20428944     DOI： 10.1007/s10620-010-1245-y

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  7 in total

1.  Rifaximin for active ulcerative colitis.

Authors:  Mario Guslandi; Maria Chiara Petrone; Pier Alberto Testoni
Journal:  Inflamm Bowel Dis       Date:  2006-04       Impact factor: 5.325

2.  Saccharomyces boulardii plus rifaximin in mesalamine-intolerant ulcerative colitis.

Authors:  Mario Guslandi
Journal:  J Clin Gastroenterol       Date:  2010 May-Jun       Impact factor: 3.062

3.  Rifaximin and Crohn's disease: a new solution to an old problem?

Authors:  A S Day; R B Gearry
Journal:  Dig Dis Sci       Date:  2010-04       Impact factor: 3.199

4.  Adjunctive antibiotic therapy with rifaximin may help reduce Crohn's disease activity.

Authors:  Ira Shafran; Patricia Burgunder
Journal:  Dig Dis Sci       Date:  2010-01-29       Impact factor: 3.199

5.  Corticosteroid-sparing effect of rifaximin, a nonabsorbable oral antibiotic, in active ulcerative colitis: Preliminary clinical experience.

Authors:  Mario Guslandi; Patrizia Giollo; Pier Alberto Testoni
Journal:  Curr Ther Res Clin Exp       Date:  2004-05

6.  Mucosal flora in inflammatory bowel disease.

Authors:  Alexander Swidsinski; Axel Ladhoff; Annelie Pernthaler; Sonja Swidsinski; Vera Loening-Baucke; Marianne Ortner; Jutta Weber; Uwe Hoffmann; Stefan Schreiber; Manfred Dietel; Herbert Lochs
Journal:  Gastroenterology       Date:  2002-01       Impact factor: 22.682

7.  Dysbiosis in inflammatory bowel disease.

Authors:  C P Tamboli; C Neut; P Desreumaux; J F Colombel
Journal:  Gut       Date:  2004-01       Impact factor: 23.059
  7 in total
  2 in total

Review 1.  FXR signaling in the enterohepatic system.

Authors:  Tsutomu Matsubara; Fei Li; Frank J Gonzalez
Journal:  Mol Cell Endocrinol       Date:  2012-05-17       Impact factor: 4.102

Review 2.  The Intricate Link among Gut "Immunological Niche," Microbiota, and Xenobiotics in Intestinal Pathology.

Authors:  Danilo Pagliari; Giovanni Gambassi; Ciriaco A Piccirillo; Rossella Cianci
Journal:  Mediators Inflamm       Date:  2017-10-08       Impact factor: 4.711
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.